I

t’s been lauded as an essential public health tool and maligned as “a party drug.” And now it’s on its way to going generic.

The Food and Drug Administration on Thursday approved Teva’s bid to market the first generic form of the daily HIV prevention pill sold as Truvada by Gilead. When it becomes available, it will be closely watched for whether it can meaningfully drive down prices and widen access — which may fuel the debate over the role the medication should play in combating HIV.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine